ReviewNature reviews. Immunology2021
A few good peptides: MHC class I-based cancer immunosurveillance and immunoevasion.
Review in Nature reviews. Immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 178 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
178 citing papers in PubMed, 1 synthesis or guideline pooled it, 264 citations in OpenAlex.
- The risk of infection-related malignancies and tumor mutational burden in immunocompromised hosts: a systematic review and meta-analysis.BMC cancer · 2026Pooled it
- Dark matter matters: from noncoding RNA regulation to cancer immunity.Oncoimmunology · 2026Review
- A PD-L1 Nanobody-Engineered Synthetic RNA Virus Enhances Hepatocellular Carcinoma Immunotherapy by Interfering PCSK9 and Upregulating MHC-I.Exploration (Beijing, China) · 2026Article
- Patient‑specific profiling of TCR‑T cell efficacy enabled by a rapid and standardized reporter system.Protein & cell · 2026Article
- The Role of IGF2BP3-Mediated Immune Response Activation in Enhancing Immunotherapy of Koumine for Gastric Cancer.Cancer science · 2026Article
- LARS2 reprograms mitochondrial metabolism and epigenetically upregulates MHC-I to boost antitumor immunity in nasopharyngeal carcinoma.Journal for immunotherapy of cancer · 2026Article
- Platelets as regulators of cancer immunity: mechanisms and therapeutic perspectives.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Bacterial mRNA Vaccines: Programming Immunity Against Antimicrobial Resistance.Drug development research · 2026Review
- Krüppel-like factor 4 downregulation during esophageal cancer formation facilitates immune evasion and impairs immunotherapy.Signal transduction and targeted therapy · 2026Article
- No evidence of immunosurveillance in mutation-hotspot-driven clonal hematopoiesis.Nature genetics · 2026Article
- Programmable mRNA 3'UTR engineering restores MHC-I and overcomes immune evasion in prostate cancer.Nature biomedical engineering · 2026Article
- Natural killer cell-mediated immunosurveillance modulates liver cancer evolution through cancer stemness enhancement and lipid metabolism reprogramming.Nature communications · 2026Article
- CXCL16-driven CD4Journal for immunotherapy of cancer · 2026Article
- Antibody Blockade of Ly49/MHC-I interactions enhances Innate and Adaptive Immunity Against Cancer Metastasis.bioRxiv : the preprint server for biology · 2026Article
- Uncoupling tumor immunogenicity from cell death with platinum(IV)-antibody conjugates.National science review · 2026Article
- Prognostic impact of HLA class I immunohistochemistry staining intensity with regard to the risk of recurrence of adenoid cystic carcinoma.Molecular and clinical oncology · 2026Article
- Human Leukocyte Antigen (HLA) and Tumor Immunity: A Critical Link in Cancer Immunotherapy.Immunity, inflammation and disease · 2026Review
- Article
- Dynamical network analysis reveals long-range residue couplings at the pMHC interface underlying enhanced immunogenicity.NPJ systems biology and applications · 2026Article
- Current Status and Future Prospects of Immune Checkpoint Inhibitors Research in the Treatment of Multiple Myeloma.Endocrine, metabolic & immune disorders drug targets · 2026Review
118 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The remarkable success of immune checkpoint inhibitors demonstrates the potential of tumour-specific CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.